Aurinia Pharmaceuticals Inc 2026年季度报告

FORM 10-Q_____________________________________________ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2026OR Aurinia Pharmaceuticals Inc. (Exact Name of Registrant as Specified in its Charter)__________________________________________ Alberta, Canada(State or other jurisdiction ofincorporation or organization)#140, 14315 - 118 AvenueEdmonton, Alberta T5L 4S6 98-1231763(I.R.S. EmployerIdentification Number) (250) 744-2487 Registrant’s telephone number, including area code_____________________________________________ Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to suchfiling requirements for the past 90 days.YesNo Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submitsuch files).YesNo Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, smaller reporting company, or anemerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growthcompany” in Rule 12b-2 of the Exchange Act. Large accelerated filerNon-accelerated filer☐Emerging growth company☐ Smallerreportingcompany If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with anynew or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).YesNo Indicate the number of shares outstanding of each of the registrant's classes of common shares, as of the latest predictable date. As of May 6, 2026,the registrant had 128,601,671 of common shares outstanding. Securities registered pursuant to Section 12(b) of the Act: Table of Contents PART I.FINANCIAL INFORMATION1Item 1.Financial Statements1Condensed Consolidated Balance Sheets as of March 31, 2026 (Unaudited) and December 31, 20251Condensed Consolidated Statements of Operations and Comprehensive Income for the Three Months EndedMarch 31, 2026 and 2025 (Unaudited)2Condensed Consolidated Statements of Shareholders’ Equity for the Three Months Ended March 31, 2026and 2025 (Unaudited)3Condensed Consolidated Statements of Cash Flows for the Three Months Ended March 31, 2026 and 2025(Unaudited)4Notes to Condensed Consolidated Financial Statements (Unaudited)5Item 2.Management’s Discussion and Analysis of Financial Condition and Results of Operations12Item 3.Quantitative and Qualitative Disclosures About Market Risk16Item 4.Controls and Procedures16PART II.OTHER INFORMATION17Item 1.Legal Proceedings17Item 1A.Risk Factors17Item 2.Unregistered Sales of Equity Securities and Use of Proceeds17Item 3.Defaults Upon Senior Securities17Item 4.Mine Safety Disclosures17Item 5.Other Information18Item 6.Exhibits18Signatures19 AURINIA PHARMACEUTICALS INC. AND SUBSIDIARYCONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE INCOME(Unaudited)(in thousands, except per share data) AURINIA PHARMACEUTICALS INC. AND SUBSIDIARYNOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS(Unaudited) 1.Organization and Description of Business Aurinia Pharmaceuticals Inc. (“Aurinia” or the “Company”) is a biopharmaceutical company focused on delivering therapies to peopleliving with autoimmune diseases with high unmet medical needs. In January 2021, the Company introduced LUPKYNIS(voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. Aurinia is alsodeveloping aritinercept, a dual inhibitor of B cell-activating factor (“BAFF”) and a proliferation-inducing ligand (“APRIL”) for thepotential treatment of autoimmune diseases.® 2.Basis of Presentation and Summary of Significant Accounting Policies Basis of Presentation, Principles of Consolidation and Use of Estimates The Company’s unaudited condensed consolidated financial statements have been prepared in accordance with generally acceptedaccounting principles in the U.S. (“U.S. GAAP”) for interim financial information and in accordance with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, certain information and disclosures required by U.S. GAAP for annual financialstatements have been omitted. In the opinion of management, all adjustments, consisting of normal recurring adjustments, considerednecessary for a fair presentation have been